Review and analysis of history and utilization of panretinal photocoagulation and ranibizumab after publication of protocol S.
Curr Opin Ophthalmol
; 35(5): 369-375, 2024 Sep 01.
Article
em En
| MEDLINE
| ID: mdl-39115058
ABSTRACT
PURPOSE OF REVIEW We describe the history, utilization, and series results of panretinal photocoagulation (PRP) and ranibizumab and provide an analysis of PRP and ranibizumab usage before versus after the publication of the 2-year and 5-year results of the Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol S trial. RECENT FINDINGS:
Number of ranibizumabs performed began to increase and number of PRPs performed began to decrease in 2016. After publication of the 2-year results, there was significant negative trend in PRP services and significant positive trend in ranibizumab services (both Pâ<â0.001). After publication of the 5-year results, there was significant negative trend in PRP services (Pâ=â0.003). There were significant negative trends (all Pâ<â0.001) in reimbursement factors for PRP from 2013 to 2020 average work RVU (wRVU), nonfacility physical expense RVU, facility PE RVU, malpractice RVU (MP RVU).SUMMARY:
Both PRP and ranibizumab have undergone numerous trials comparing their efficacy to other treatment options or no treatment at all. The publication of the 2-year results of Protocol S was associated with an increase in utilization of ranibizumab and decrease in utilization of PRP, with continued decrease after the publication of the 5-year results.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fotocoagulação a Laser
/
Inibidores da Angiogênese
/
Retinopatia Diabética
/
Injeções Intravítreas
/
Ranibizumab
Limite:
Humans
Idioma:
En
Revista:
Curr Opin Ophthalmol
Ano de publicação:
2024
Tipo de documento:
Article